ТЕРАПИЯ ПРИ ОСТРОМ ЛИМФОБЛАСТНОМ ЛЕЙКОЗЕ
Аннотация
Приведены основные современные протоколы терапии острого лимфобластного лейкоза (ОЛЛ) с учетом возраста, соматического статуса пациентов, варианта ОЛЛ и цитогенетических групп риска. Учтены показания для трансплантации гемопоэтических стволовых клеток (ТГСК) в зависимости от наличия ремиссии и типа донора.
Литература
Эффективность протокола ALL-MB-2002 у детей с острым лимфобластным лейкозом / Ю. В. Румянцева [и др.] // Тер. архив. – 2010. – Т. 82. – № 7. – С. 11-19.
Bassan, R. Modern Therapy of Acute Lymphoblastic Leukemia / R. Bassan, D. Hoelzer // J. of Clin. Oncology. – 2011. – Vol. 29, № 5. – Р. 532-544.
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy leukemia group protocol 09.00 / Bassan R. [et al] // J. Clin. Oncol. – 2010. – Vol. 28, № 3. – P. 644-3652.
Dasatinid as first line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients: Final results of the GIMEMA LAL 1205 Study / R. Foa [et al] // Blood. – 2008. – Vol. 112, № 1. – Р. 112-119.
End point to establish in the efficacy of new agents in the treatment of acute leukemia./Appelbaum F. R. [et al] // Blood. – 2007. – № 109. – P. 1810-1816.
Gokbuget, N. How I treat older patients with ALL / N. Gokbuget // Blood. – 2013. – № 122. – Р. 1366-1375.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group / M. Yanada [et al] // Journal of Clinical Oncology. – 2006. – Vol. 24, № 3. – Р. 460-466.
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study / A. de Labarthe [et al] // Blood. – 2007. – Vol. 109, № 4. – Р. 1408-1413.
Imatinib plus steroids induces complete remission and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell, Adulto (GIMEMA) LAL 0201-B protocol / M. Vignetti [et al] // Blood. – 2007. – Vol. 109. – Р. 3676-3678.
Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD 20+ B-lineage standard and high risk patients: results of 263 CD 20+ patients studied prospectively in GMALL study 07/2003 / D. Hoelzer [et al] // Blood. – 2010. – Vol. 116. – № 1. – Р. 170.
Improved outcome in adult B-cell acute lymphoblastic leukemia / D. Hoelzer [et al] // Blood. – 1996. – № 87. – Р. 495-508.
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is associated from a matched sibling allogenic transplantation in first complete remission, and an autologous transplantation is less effective then conventional consolidation/maintenance chemotherapy in all pаtients: final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993) / A.H. Goldstone [et al] // Blood. – 2008. – Vol. 111, № 4. – Р. 1827-1833.
Lee, K. H. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia / K. H. Lee, J.H. Lee, S.J. Choi // Leukemia. – 2005. – № 19. – Р. 1509-1516.
Long-term outcome after Hyper-CVAD and rityximab chemoimmunotherapy for Bukitt (BL) or Burkitt-like (BLL) leukemia-lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL) / D. A. Thomas [et al] // Blood. – 2007. – Vol. 110. – Р. 831 – (abstr. 2825).
Marks, D. I. Treating the «Older» Adults with Acute Lymphoblastic Leukemia / D. I. Marks // Hematology (ASH Education Program). – 2010, № 1. – Р. 13-20
Myeloablative allogenic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison / J. J. Cornelissen [et al] // Blood. – 2009. – Vol. 113, № 6. – Р. 1375-1382.
Neralabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study / D. J. DeAngelo [et al] // Blood. – 2007. – № 103. – Р. 5136-5142.
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study / Fielding A. K.[et al.] // Blood. – 2007. – Vol. 110(13). – P. 944-950.
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study / F. J. Huguet [et al] // Clin. Oncol. – 2009. – № 27. – Р. 911-918.
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults / Hoelzer D.[et al] // Blood. – 1988. – Vol. 71. – P. 123-131.
Reduced-intensity versus conventional myeloablative conditioning allogenic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from European Group for Blood and Marrow Transplantation / M. Mohty [et al] // Blood. – 2010. – Vol. 116, № 22. – Р. 4439- 4443.
Report of a phase II trial of single-agent BiTE(R) antibody blinotumomab in patients with minimal residual disease (МRD) positive B-precursor acute lymphoblastic leukemia (ALL) / M.S. Topp [et al] // Blood. – 2009. – Vol. 114. – Р. 346 (abstr. 840).
Successful subtype oriented treatment strategies in adult T-ALL: Results of 774 patients treated in three constcutive GMALL studies / D. Hoelzer [et al] // Blood. – 2009. – Vol. 114, № 13. – Р. 324-327.
